Association of Hypertension with Different Cognitive Disorders
- PMID: 39457979
- PMCID: PMC11514732
- DOI: 10.3390/jcm13206029
Association of Hypertension with Different Cognitive Disorders
Abstract
This literature review explores the association between hypertension and major neurocognitive disorders, including delirium, Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal dementia, which contribute significantly to global mortality and morbidity. Hypertension is a potentially modifiable risk factor for cognitive decline, as it contributes to the progression of neurodegenerative pathologies via vascular damage, inflammation, and the disruption of the blood-brain barrier. Despite this, the effectiveness of antihypertensive treatments in preventing or alleviating cognitive decline remains contentious. While some research highlights the potential benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, other studies show inconsistent results, complicated by variations in hypertension definitions, diagnostic criteria for cognitive disorders, and confounding factors like medication adherence. Furthermore, the complex bidirectional relationship between hypertension and major neurocognitive disorders warrants more investigation, as cognitive decline can exacerbate cardiovascular risks through heightened inflammatory responses and compromised autonomic regulation. This review underscores the need for prospective, long-term studies to elucidate the relationships between hypertension and cognitive disorders and to evaluate the potential therapeutic benefits of antihypertensive treatments.
Keywords: Alzheimer’s; Lewy body; antihypertensive; dementia; frontotemporal; hypertension; vascular.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Cardiovascular Disease and Dementia: Exploring Intersections, Risks, and Therapeutic Challenges.Cardiol Rev. 2024 May 24. doi: 10.1097/CRD.0000000000000730. Online ahead of print. Cardiol Rev. 2024. PMID: 38785445
-
Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.J Alzheimers Dis. 2022;89(2):709-719. doi: 10.3233/JAD-220439. J Alzheimers Dis. 2022. PMID: 35912747
-
Treatment options and considerations for hypertensive patients to prevent dementia.Expert Opin Pharmacother. 2017 Jul;18(10):989-1000. doi: 10.1080/14656566.2017.1333599. Epub 2017 May 29. Expert Opin Pharmacother. 2017. PMID: 28532183 Review.
-
Antihypertensive treatments, cognitive decline, and dementia.J Alzheimers Dis. 2010;20(3):903-14. doi: 10.3233/JAD-2010-091552. J Alzheimers Dis. 2010. PMID: 20182022 Review.
-
Chronic Renin-Angiotensin System Activation Induced Neuroinflammation: Common Mechanisms Underlying Hypertension and Dementia?J Alzheimers Dis. 2022;85(3):943-955. doi: 10.3233/JAD-215231. J Alzheimers Dis. 2022. PMID: 34897090 Review.
Cited by
-
Mechanisms of cognitive impairment in arterial hypertension.World J Psychiatry. 2025 Jul 19;15(7):106597. doi: 10.5498/wjp.v15.i7.106597. eCollection 2025 Jul 19. World J Psychiatry. 2025. PMID: 40740466 Free PMC article.
-
Relationship between diastolic blood pressure and Alzheimer disease: A 2-sample Mendelian randomization study based on an automated screening method for exposure factors and empirical validation.Medicine (Baltimore). 2024 Dec 6;103(49):e40765. doi: 10.1097/MD.0000000000040765. Medicine (Baltimore). 2024. PMID: 39654245 Free PMC article.
-
Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment.Pharmaceutics. 2025 Feb 20;17(3):284. doi: 10.3390/pharmaceutics17030284. Pharmaceutics. 2025. PMID: 40142948 Free PMC article. Review.
References
-
- American Psychiatric Association . DSM-5-TR Classification. Volume 14. American Psychiatric Association Publishing; Washington, DC, USA: 2022. p. 161.
Publication types
LinkOut - more resources
Full Text Sources